IGLVI-70: A Potential Drug Target for Neurodegenerative Diseases

Target Name: IGLVI-70

NCBI ID: G28763

IGLVI-70

Other Name(s): IGLV(I)-70 | Immunoglobulin lambda variable (I)-70 (pseudogene) | IGLVI70 | immunoglobulin lambda variable (I)-70 (pseudogene) | V1-27P

IGLVI-70: A Potential Drug Target for Neurodegenerative Diseases

IGLVI-70 (Igllvi-70) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the Integrin alpha-6 (Igllvi) family, which is a subfamily of integrins that are involved in cell-cell and cell-extracellular matrix adhesion.

IGLVI-70 has been identified as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to the development of new therapeutic strategies, such as monoclonal antibodies (MAs) and small interfering RNA (siRNA) therapies.

One of the key benefits of IGLVI-70 as a drug target is its expression in a wide range of tissues, which makes it an attractive target for therapeutic intervention. IGLVI-70 is expressed in brain, heart, lung, and gastrointestinal tract tissues, making it a potential target for drugs that can modulate its expression and activity in these tissues.

IGLVI-70 is also involved in several important biological processes in the body, including cell adhesion, migration, and invasion. Its role in these processes has led to its potential as a drug target for diseases that are characterized by the disruption of these processes, such as cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, IGLVI-70 has also been shown to have several potential biochemical and cellular functions. For example, IGLVI-70 has been shown to play a role in the regulation of cell proliferation, apoptosis, and angiogenesis. It has also been shown to interact with several intracellular signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

The identification of IGLVI-70 as a potential drug target has led to a significant increase in research on its mechanisms of action and potential therapeutic applications. ongoing clinical trials are evaluating the safety and efficacy of MAb-conjugated antibodies against IGLVI-70 in a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

In conclusion, IGLVI-70 is a protein that has the potential to be a drug target for a wide range of diseases due to its involvement in several important biological processes in the body, including cell adhesion, migration, and invasion. Its potential as a drug target is further supported by its expression in a wide range of tissues and its involvement in several important biological processes. Further research is needed to fully understand its mechanisms of action and potential therapeutic applications.

Protein Name: Immunoglobulin Lambda Variable (I)-70 (pseudogene)

The "IGLVI-70 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLVI-70 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets